177 related articles for article (PubMed ID: 9143315)
1. E7 oncoprotein of human papillomavirus type 16 expressed constitutively in the epidermis has no effect on E7-specific B- or Th-repertoires or on the immune response induced or sustained after immunization with E7 protein.
Herd K; Fernando GJ; Dunn LA; Frazer IH; Lambert P; Tindle RW
Virology; 1997 Apr; 231(1):155-65. PubMed ID: 9143315
[TBL] [Abstract][Full Text] [Related]
2. Immunological responses in human papillomavirus 16 E6/E7-transgenic mice to E7 protein correlate with the presence of skin disease.
Frazer IH; Leippe DM; Dunn LA; Liem A; Tindle RW; Fernando GJ; Phelps WC; Lambert PF
Cancer Res; 1995 Jun; 55(12):2635-9. PubMed ID: 7540107
[TBL] [Abstract][Full Text] [Related]
3. Low level expression of human papillomavirus type 16 (HPV16) E6 in squamous epithelium does not elicit E6 specific B- or T-helper immunological responses, or influence the outcome of immunisation with E6 protein.
Azoury-Ziadeh R; Herd K; Fernando GJ; Lambert P; Frazer IH; Tindle RW
Virus Res; 2001 Mar; 73(2):189-99. PubMed ID: 11172923
[TBL] [Abstract][Full Text] [Related]
4. Mice expressing the E7 oncogene of HPV16 in epithelium show central tolerance, and evidence of peripheral anergising tolerance, to E7-encoded cytotoxic T-lymphocyte epitopes.
Doan T; Chambers M; Street M; Fernando GJ; Herd K; Lambert P; Tindle R
Virology; 1998 May; 244(2):352-64. PubMed ID: 9601506
[TBL] [Abstract][Full Text] [Related]
5. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides.
Ressing ME; Sette A; Brandt RM; Ruppert J; Wentworth PA; Hartman M; Oseroff C; Grey HM; Melief CJ; Kast WM
J Immunol; 1995 Jun; 154(11):5934-43. PubMed ID: 7538538
[TBL] [Abstract][Full Text] [Related]
6. Chimeric hepatitis B core antigen particles containing B- and Th-epitopes of human papillomavirus type 16 E7 protein induce specific antibody and T-helper responses in immunised mice.
Tindle RW; Herd K; Londoño P; Fernando GJ; Chatfield SN; Malcolm K; Dougan G
Virology; 1994 May; 200(2):547-57. PubMed ID: 7513919
[TBL] [Abstract][Full Text] [Related]
7. Induction of human papilloma virus E6/E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6/E7-transgenic mice.
Riezebos-Brilman A; Regts J; Freyschmidt EJ; Dontje B; Wilschut J; Daemen T
Gene Ther; 2005 Sep; 12(18):1410-4. PubMed ID: 15843807
[TBL] [Abstract][Full Text] [Related]
8. Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection.
Kim TY; Myoung HJ; Kim JH; Moon IS; Kim TG; Ahn WS; Sin JI
Cancer Res; 2002 Dec; 62(24):7234-40. PubMed ID: 12499264
[TBL] [Abstract][Full Text] [Related]
9. Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7.
Daemen T; Pries F; Bungener L; Kraak M; Regts J; Wilschut J
Gene Ther; 2000 Nov; 7(21):1859-66. PubMed ID: 11110419
[TBL] [Abstract][Full Text] [Related]
10. Presentation of the HPV16E7 protein by skin grafts is insufficient to allow graft rejection in an E7-primed animal.
Dunn LA; Evander M; Tindle RW; Bulloch AL; de Kluyver RL; Fernando GJ; Lambert PF; Frazer IH
Virology; 1997 Aug; 235(1):94-103. PubMed ID: 9300040
[TBL] [Abstract][Full Text] [Related]
11. Th2-type CD4+ cells neither enhance nor suppress antitumor CTL activity in a mouse tumor model.
Fernando GJ; Stewart TJ; Tindle RW; Frazer IH
J Immunol; 1998 Sep; 161(5):2421-7. PubMed ID: 9725239
[TBL] [Abstract][Full Text] [Related]
12. T-helper epitopes identified within the E6 transforming protein of cervical cancer-associated human papillomavirus type 16.
Azoury-Ziadeh R; Herd K; Fernando GJ; Frazer IH; Tindle RW
Viral Immunol; 1999; 12(4):297-312. PubMed ID: 10630789
[TBL] [Abstract][Full Text] [Related]
13. "Natural" presentation of human papillomavirus type-16 E7 protein to immunocompetent mice results in antigen-specific sensitization or sustained unresponsiveness.
Chambers MA; Wei Z; Coleman N; Nash AA; Stanley MA
Eur J Immunol; 1994 Mar; 24(3):738-45. PubMed ID: 8125141
[TBL] [Abstract][Full Text] [Related]
14. Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7.
Daemen T; Regts J; Holtrop M; Wilschut J
Gene Ther; 2002 Jan; 9(2):85-94. PubMed ID: 11857066
[TBL] [Abstract][Full Text] [Related]
15. Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter.
Welters MJ; de Jong A; van den Eeden SJ; van der Hulst JM; Kwappenberg KM; Hassane S; Franken KL; Drijfhout JW; Fleuren GJ; Kenter G; Melief CJ; Offringa R; van der Burg SH
Cancer Res; 2003 Feb; 63(3):636-41. PubMed ID: 12566307
[TBL] [Abstract][Full Text] [Related]
16. Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: effects of the route of immunization.
Daemen T; Riezebos-Brilman A; Regts J; Dontje B; van der Zee A; Wilschut J
Antivir Ther; 2004 Oct; 9(5):733-42. PubMed ID: 15535411
[TBL] [Abstract][Full Text] [Related]
17. Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway.
Peng S; Frazer IH; Fernando GJ; Zhou J
Virology; 1998 Jan; 240(1):147-57. PubMed ID: 9448699
[TBL] [Abstract][Full Text] [Related]
18. Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16.
Chen L; Mizuno MT; Singhal MC; Hu SL; Galloway DA; Hellström I; Hellström KE
J Immunol; 1992 Apr; 148(8):2617-21. PubMed ID: 1313847
[TBL] [Abstract][Full Text] [Related]
19. Codon optimized expression of HPV 16 E6 renders target cells susceptible to E6-specific CTL recognition.
Samorski R; Gissmann L; Osen W
Immunol Lett; 2006 Sep; 107(1):41-9. PubMed ID: 16949679
[TBL] [Abstract][Full Text] [Related]
20. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells.
Feltkamp MC; Smits HL; Vierboom MP; Minnaar RP; de Jongh BM; Drijfhout JW; ter Schegget J; Melief CJ; Kast WM
Eur J Immunol; 1993 Sep; 23(9):2242-9. PubMed ID: 7690326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
